FDA Boxed Warning — Risk of Thyroid C-Cell Tumors
Tirzepatide caused thyroid C-cell tumors in rats at clinically relevant exposures. Relevance to humans has not been determined. Contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Other labeled risks: pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), severe gastrointestinal events (severe gastroparesis, intestinal obstruction reports), acute kidney injury, hypersensitivity reactions, hypoglycemia when combined with insulin/sulfonylureas, diabetic retinopathy complications in patients with pre-existing disease. See the full FDA label on DailyMed before any protocol design.
Tirzepatide Protocol Guide
Tirzepatide is a dual GIP and GLP-1 receptor agonist studied for metabolic research. This starting-size vial is ideal for initial dosing protocols.
Protocol Overview
- Compound
- Tirzepatide (Research Peptide for Metabolic Studies)
- Category
- Dual GIP/GLP-1 Receptor Agonist
- Vial Size
- 5mg (5,000mcg)
- Reconstitution
- 1mL bacteriostatic water (5mg/mL)
- Route
- Subcutaneous injection
- Frequency
- Once weekly
Reconstitution Instructions
Reconstitution volume depends on vial size. For a 10mg vial, adding 2mL of bacteriostatic water yields 5mg/mL. For a 5mg vial, adding 1mL yields 5mg/mL. Always use sterile techniques.
Materials Needed
- Tirzepatide vial (lyophilized powder — typically 5mg, 10mg, or 15mg)
- Bacteriostatic water (sterile, preserved with 0.9% benzyl alcohol)
- Sterile syringe and needle (18-22 gauge for drawing)
- Alcohol swabs
- Clean workspace
Step-by-Step Process
- Preparation: Allow the Tirzepatide 5mg vial and bacteriostatic water to reach room temperature. Wipe the rubber stoppers of both vials with an alcohol swab.
- Draw the Water: Using a sterile syringe, draw up exactly 1mL of bacteriostatic water. Expel any air bubbles.
- Inject into Vial: Insert the needle through the rubber stopper at a slight angle, aiming toward the glass wall. Slowly inject the water down the side of the vial to avoid foaming.
- Mix Gently: Remove the needle. Gently swirl or roll the vial between your hands. Do not shake vigorously.
- Check for Clarity: The solution should be clear once fully reconstituted. Do not use if cloudy.
Weekly Dosing Schedule (Titration Protocol)
Tirzepatide follows a dose-escalation protocol. Start at 2.5mg once weekly and increase every 4 weeks as tolerated.
| Weeks | Dose | Units (at 5mg/mL) | Frequency |
|---|---|---|---|
| Weeks 1–4 | 2.5mg | 50 units (0.5mL) | Once weekly |
| Weeks 5–8 | 5mg | 100 units (1.0mL) | Once weekly |
| Weeks 9–12 | 7.5mg | Use 10mg/mL concentration | Once weekly |
| Weeks 13–16 | 10mg | Use 10mg/mL concentration | Once weekly |
| Weeks 17–20 | 12.5mg | Use 10mg/mL concentration | Once weekly |
| Weeks 21+ | 15mg (max) | Use 10mg/mL concentration | Once weekly |
Starting dose: 2.5mg once weekly • A 5mg vial provides 2 doses at 2.5mg • A 10mg vial provides 4 doses at 2.5mg or 2 doses at 5mg
Quick Dosing Reference (at 5mg/mL concentration)
| Units (Ticks) | Dose (mcg) | Dose (mg) |
|---|---|---|
| 10 | 500 | 0.5mg |
| 25 | 1,250 | 1.25mg |
| 50 | 2,500 | 2.5mg |
| 75 | 3,750 | 3.75mg |
| 100 | 5,000 | 5mg |
For doses above 5mg, use a higher concentration (e.g., 10mg/mL) or multiple injections. Consult a dosing calculator for larger vials.
Administration Guidelines
- Administer subcutaneously once weekly on the same day each week
- Rotate injection sites between abdomen, thigh, and upper arm
- Start at 2.5mg weekly and titrate up every 4 weeks
- Store reconstituted peptide refrigerated at 36-46F (2-8C)
- Use reconstituted solution within 30 days
- Never freeze reconstituted peptides
- Document administration times and observations
Storage Requirements
| State | Storage Conditions |
|---|---|
| Lyophilized (powder) | Room temperature or refrigerated, protect from light |
| Reconstituted | Refrigerated 36-46F (2-8C), use within 30 days |